Antigens, CD56
-
Subject Areas on Research
- A one-step large-scale method for T- and B-cell depletion of mobilized PBSC for allogeneic transplantation.
- A placebo-controlled trial of ranitidine in patients with early human immunodeficiency virus infection.
- Alpha-glycosylceramides enhance the antitumor cytotoxicity of hepatic lymphocytes obtained from cancer patients by activating CD3-CD56+ NK cells in vitro.
- CD58/LFA-3 and IL-12 provided by activated monocytes are critical in the in vitro expansion of CD56+ T cells.
- Glioblastoma with PNET-like components has a higher frequency of isocitrate dehydrogenase 1 (IDH1) mutation and likely a better prognosis than primary glioblastoma.
- High frequency of immunophenotype changes in acute myeloid leukemia at relapse: implications for residual disease detection (Cancer and Leukemia Group B Study 8361).
- Human placental cytotrophoblasts attract monocytes and CD56(bright) natural killer cells via the actions of monocyte inflammatory protein 1alpha.
- Induction of CD56 and TCR-independent activation of T cells with aging.
- Metastatic Merkel cell carcinoma (MCC) of pancreas and breast: a unique case.
- Natural killer cells in vernal keratoconjunctivitis.
- Neural cell adhesion molecule (CD56)-positive acute myelogenous leukemia and myelodysplastic and myeloproliferative syndromes.
- Phase I clinical and pharmacokinetic trial of flavone acetic acid.
- Resistance of pancreatic carcinoma cells is reversed by coculturing NK-like T cells with dendritic cells pulsed with tumor-derived RNA and CA 19-9.
- Selective modulation of human natural killer cells in vivo after prolonged infusion of low dose recombinant interleukin 2.
- Sequential gene profiling of basal cell carcinomas treated with imiquimod in a placebo-controlled study defines the requirements for tissue rejection.